- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN0905 | Recombinant Protein-Human immunodeficiency virus 1 HIV-1 env gp41 (a.a.1 to 129) | AAQ63673 | 100 µg | 1195 | |
PN0906 | Recombinant Protein-Human immunodeficiency virus 1 HIV Reverse Transcriptase (a.a.1 to 560) | NP_705927 | 100 µg | 1195 | |
PN0907 | Recombinant Protein-Human immunodeficiency virus 1 nef protein (a.a.1 to 205) | AAL12764 | 100 µg | 1195 | |
PN0908 | Recombinant Protein-Human immunodeficiency virus 1 HIV-1 gag p24 (a.a.133 to 363) | Q70622 | 100 µg | 1195 | |
PN0909 | Recombinant Protein-Human immunodeficiency virus 1 Surface protein gp120 (a.a.24 to 515) | Q6S7U7 | 100 µg | 1195 | |
PN0910 | Recombinant Protein-Human immunodeficiency virus 1 Surface protein gp120 (a.a.30 to 513) | Q9YUL5 | 100 µg | 1195 | |
PN0911 | Recombinant Protein-Human immunodeficiency virus 1 Surface protein gp120 (a.a.30 to 503) | Q6BC04 | 100 µg | 1195 | |
PN0912 | Recombinant Protein-Human immunodeficiency virus 1 Surface protein gp120 (a.a.32 to 494) | Q6BC58 | 100 µg | 1195 | |
PN0913 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 gag-p17-p24-p15-fusion (a.a.77 to 436) | Q70622 | 100 µg | 1195 | |
PN0914 | Recombinant Protein-Human immunodeficiency virus type 1 Matrix protein p17 (a.a.2 to 130) | Q77373 | 100 µg | 1195 | |
PN0915 | Recombinant Protein-Human immunodeficiency virus type 1 Capsid protein p24 (a.a.131 to 362) | Q77373 | 100 µg | 1195 | |
PN0916 | Recombinant Protein-Human immunodeficiency virus type 1 Reverse transcriptase (a.a.587 to 1146) | Q77373 | 100 µg | 1195 | |
PN0917 | Recombinant Protein-Human immunodeficiency virus type 1 p51 RT (a.a.587 to 1026) | Q77373 | 100 µg | 1195 | |
PN0918 | Recombinant Protein-Human immunodeficiency virus type 1 p15 (a.a.1027 to 1146) | Q77373 | 100 µg | 1195 | |
PN0919 | Recombinant Protein-Human immunodeficiency virus type 1 Integrase (a.a.1147 to 1435) | Q77373 | 100 µg | 1195 | |
PN0920 | Recombinant Protein-Human immunodeficiency virus type 1 Protease (a.a.488 to 586) | Q77373 | 100 µg | 1195 | |
PN0921 | Recombinant Protein-Human immunodeficiency virus type 1 Protein Tat (a.a.1 to 114) | P0C1K1 | 100 µg | 1195 | |
PN0922 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Matrix protein p17 (a.a.2 to 132) | P04585 | 100 µg | 1195 | |
PN0923 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Capsid protein p24 (a.a.133 to 363) | P04585 | 100 µg | 1195 | |
PN0924 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Nucleocapsid protein p7 (a.a.378 to 432) | P04585 | 100 µg | 1195 | |
PN0925 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Protease (a.a.489 to 587) | P04585 | 100 µg | 1195 | |
PN0926 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 p15 (a.a.1028 to 1147) | P04585 | 100 µg | 1195 | |
PN0927 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Integrase (a.a.1148 to 1435) | P04585 | 100 µg | 1195 | |
PN0928 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Surface protein gp120 + gp41 (a.a.471 to 684) | P04578 | 100 µg | 1195 | |
PN0929 | Recombinant Protein-Human immunodeficiency virus type 1 HIV-1 Protein Tat (a.a.1 to 86) | P04608 | 100 µg | 1195 | |
PN0930 | Recombinant Protein-Human immunodeficiency virus type 1 Envelope glycoprotein gp120 +gp41 (a.a.470 to 748) | Q79670 | 100 µg | 1195 | |
PN0931 | Recombinant Protein-Human immunodeficiency virus type Surface protein gp120 (a.a.32 to 498) | P35961 | 100 µg | 1195 | |
PN0932 | Recombinant Protein-Human immunodeficiency virus type 2 HIV-2 env gp160+gp36 (a.a.388 to 672) | P04577 | 100 µg | 1195 | |
PN0933 | Recombinant Protein-Human immunodeficiency virus type 2 HIV-2 env gp41 (a.a.502 to 851) | P17755 | 100 µg | 1195 | |
RPN0905 | cDNA-Human immunodeficiency virus 1 HIV-1 env gp41 (a.a.1 to 129) | AAQ63673 | 2 µg | 800 | |
RPN0906 | cDNA-Human immunodeficiency virus 1 HIV Reverse Transcriptase (a.a.1 to 560) | NP_705927 | 2 µg | 2795 | |
RPN0907 | cDNA-Human immunodeficiency virus 1 nef protein (a.a.1 to 205) | AAL12764 | 2 µg | 1020 | |
RPN0908 | cDNA-Human immunodeficiency virus 1 HIV-1 gag p24 (a.a.133 to 363) | Q70622 | 2 µg | 1150 | |
RPN0909 | cDNA-Human immunodeficiency virus 1 Surface protein gp120 (a.a.24 to 515) | Q6S7U7 | 2 µg | 2455 | |
RPN0910 | cDNA-Human immunodeficiency virus 1 Surface protein gp120 (a.a.30 to 513) | Q9YUL5 | 2 µg | 2415 | |
RPN0911 | cDNA-Human immunodeficiency virus 1 Surface protein gp120 (a.a.30 to 503) | Q6BC04 | 2 µg | 2365 | |
RPN0912 | cDNA-Human immunodeficiency virus 1 Surface protein gp120 (a.a.32 to 494) | Q6BC58 | 2 µg | 2310 | |
RPN0913 | cDNA-Human immunodeficiency virus type 1 HIV-1 gag-p17-p24-p15-fusion (a.a.77 to 436) | Q70622 | 2 µg | 1795 | |
RPN0914 | cDNA-Human immunodeficiency virus type 1 Matrix protein p17 (a.a.2 to 130) | Q77373 | 2 µg | 800 | |
RPN0915 | cDNA-Human immunodeficiency virus type 1 Capsid protein p24 (a.a.131 to 362) | Q77373 | 2 µg | 1155 | |
RPN0916 | cDNA-Human immunodeficiency virus type 1 Reverse transcriptase (a.a.587 to 1146) | Q77373 | 2 µg | 2795 | |
RPN0917 | cDNA-Human immunodeficiency virus type 1 p51 RT (a.a.587 to 1026) | Q77373 | 2 µg | 2195 | |
RPN0918 | cDNA-Human immunodeficiency virus type 1 p15 (a.a.1027 to 1146) | Q77373 | 2 µg | 800 | |
RPN0919 | cDNA-Human immunodeficiency virus type 1 Integrase (a.a.1147 to 1435) | Q77373 | 2 µg | 1440 | |
RPN0920 | cDNA-Human immunodeficiency virus type 1 Protease (a.a.488 to 586) | Q77373 | 2 µg | 800 | |
RPN0921 | cDNA-Human immunodeficiency virus type 1 Protein Tat (a.a.1 to 114) | P0C1K1 | 2 µg | 800 | |
RPN0922 | cDNA-Human immunodeficiency virus type 1 HIV-1 Matrix protein p17 (a.a.2 to 132) | P04585 | 2 µg | 800 | |
RPN0923 | cDNA-Human immunodeficiency virus type 1 HIV-1 Capsid protein p24 (a.a.133 to 363) | P04585 | 2 µg | 1150 | |
RPN0924 | cDNA-Human immunodeficiency virus type 1 HIV-1 Nucleocapsid protein p7 (a.a.378 to 432) | P04585 | 2 µg | 800 | |
RPN0925 | cDNA-Human immunodeficiency virus type 1 HIV-1 Protease (a.a.489 to 587) | P04585 | 2 µg | 800 | |
RPN0926 | cDNA-Human immunodeficiency virus type 1 HIV-1 p15 (a.a.1028 to 1147) | P04585 | 2 µg | 800 | |
RPN0927 | cDNA-Human immunodeficiency virus type 1 HIV-1 Integrase (a.a.1148 to 1435) | P04585 | 2 µg | 1435 | |
RPN0928 | cDNA-Human immunodeficiency virus type 1 HIV-1 Surface protein gp120 + gp41 (a.a.471 to 684) | P04578 | 2 µg | 1065 | |
RPN0929 | cDNA-Human immunodeficiency virus type 1 HIV-1 Protein Tat (a.a.1 to 86) | P04608 | 2 µg | 800 | |
RPN0930 | cDNA-Human immunodeficiency virus type 1 Envelope glycoprotein gp120 +gp41 (a.a.470 to 748) | Q79670 | 2 µg | 1390 | |
RPN0931 | cDNA-Human immunodeficiency virus type Surface protein gp120 (a.a.32 to 498) | P35961 | 2 µg | 2330 | |
RPN0932 | cDNA-Human immunodeficiency virus type 2 HIV-2 env gp160+gp36 (a.a.388 to 672) | P04577 | 2 µg | 1420 | |
RPN0933 | cDNA-Human immunodeficiency virus type 2 HIV-2 env gp41 (a.a.502 to 851) | P17755 | 2 µg | 1745 |
Human immunodeficiency virus cDNA and recombinant antigen
HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, causing a gradual decline in the body’s ability to fight off infections and diseases. This can lead to AIDS (acquired immunodeficiency syndrome), which is the most advanced stage of HIV infection. HIV is primarily transmitted through sexual contact, blood transfusions, sharing of contaminated needles, or from mother to child during pregnancy, childbirth, or breastfeeding. There is no cure for AIDS, but antiretroviral therapy can effectively control the virus and slow the progression of the disease.
HIV antigen refers to a protein that is present on the surface of the virus. Antigens are recognized by the immune system and trigger an immune response, producing antibodies to fight the virus. In the case of HIV, the antigen is called p24. Testing for the presence of p24 antigens in the blood can detect early infections before antibodies are produced, making it an effective way to diagnose HIV.
The HIV genome is the complete genetic material (DNA) of the virus. It is composed of RNA, which is reverse transcribed into DNA once the virus infects a host cell. The HIV genome contains 9 genes that encode for essential proteins involved in the replication and pathogenesis of the virus. The genetic variability of HIV is high, and the mutations that occur over time contribute to the evolution of the virus and the development of drug resistance. Understanding the HIV genome is crucial for developing effective antiviral therapies and vaccines against the virus. The virus is composed of various proteins, including:
Env gp41: a glycoprotein that is involved in the fusion of the viral and host cell membranes.
Reverse Transcriptase: an enzyme that converts the viral RNA genome into DNA.
Nef protein: a regulatory protein that modifies the host cell environment to enhance viral replication and evade the immune response.
Gag proteins: a group of structural proteins that form the core of the virus, including HIV-1 gag p24, HIV-1 gag-p17-p24-p15-fusion, Matrix protein p17, Capsid protein p24, and Nucleocapsid protein.
Surface protein gp120: a glycoprotein that binds to the host cell receptor CD4 and co-receptor, initiating viral entry.
Reverse transcriptase (p51 RT): a component of the reverse transcriptase enzyme that is involved in the conversion of RNA to DNA
p15: a small matrix protein involved in virus assembly and budding.
Integrase: an enzyme that is responsible for integrating the viral DNA into the host cell genome.
Protease: an enzyme that cleaves viral precursor proteins to generate mature viral proteins, including Matrix protein p17 and Capsid protein p24.
Protein Tat: a regulatory protein that is required for efficient viral transcription.
In addition, HIV-2, another strain of HIV, contains proteins such as HIV-2 env gp160+gp36 and HIV-2 env gp41, which are involved in viral entry and fusion.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple
